Neurodegeneration and chronic pain are significant medical problems that ensue from activation of the innate immune system chemokine receptors. Our latest advances deliver receptor-active peptides (“RAPs”) that safely block several chemokine receptors to stop neurodegeneration and promote neuroregeneration. CPB’s research platform consists of a collection of small oral peptides suitable for 1x daily dosing that are potent antagonists of multiple disease-causing chemokine receptors. These peptides are being developed to treat chronic pain, Alzheimer’s and Parkinson’s Diseases. We are showing that these same chemokine receptor pathways control reward pathways and animal drug-seeking behaviors. Blocking chemokine activation in the brain is opening a new class of treatments for treating opioid and other substance abuse disorders.